PBLS – Parabilis Medicines Inc

[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=PBLS#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]

PBLS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.22

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

27.77

Target Price

Analyst Recom

Performance Q

Upside

N/A

Beta

Ticker: PBLS

12 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-15	PBLS	25.01	N/A	N/A	0
2026-06-16	PBLS	26.57	N/A	N/A	0
2026-06-17	PBLS	26.06	N/A	N/A	0
2026-06-18	PBLS	25.97	N/A	N/A	0
2026-06-22	PBLS	27.49	N/A	N/A	0
2026-06-23	PBLS	27.41	N/A	N/A	0
2026-06-24	PBLS	27.38	N/A	N/A	0
2026-06-25	PBLS	26.28	N/A	N/A	0
2026-06-26	PBLS	29.01	N/A	N/A	0
2026-06-29	PBLS	29.43	N/A	N/A	0
2026-06-30	PBLS	27.29	N/A	N/A	0
2026-07-01	PBLS	27.75	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

12 items 1 of 1

12 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-15	PBLS	25.07	-	-	-
2026-06-16	PBLS	26.49	-	-	-
2026-06-17	PBLS	26.00	-	-	-
2026-06-18	PBLS	25.81	-	-	-
2026-06-22	PBLS	27.52	-	-	-
2026-06-23	PBLS	27.51	-	-	-
2026-06-24	PBLS	27.25	-	-	-
2026-06-25	PBLS	26.29	-	-	-
2026-06-26	PBLS	28.82	-	-	-
2026-06-29	PBLS	29.24	-	-	-
2026-06-30	PBLS	27.29	-	-	-
2026-07-01	PBLS	27.77	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

12 items 1 of 1

12 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-15	PBLS	0	0	0
2026-06-16	PBLS	0	0	0
2026-06-17	PBLS	0	0	0
2026-06-18	PBLS	0	0	0
2026-06-22	PBLS	376.44	0	0
2026-06-23	PBLS	376.44	0	0
2026-06-24	PBLS	376.44	0	0
2026-06-25	PBLS	376.44	0	0
2026-06-26	PBLS	374.86	0	1.22
2026-06-29	PBLS	420.88	0	1.22
2026-06-30	PBLS	420.88	0	1.22
2026-07-01	PBLS	420.88	0	1.22
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

12 items 1 of 1

[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=PBLS 589 360 ]

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

420.88

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

19.4

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.41

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-96.6

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[iframe https://widget.finnhub.io/widgets/recommendation?symbol=PBLS 589 450 ]

[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=PBLS 589 450 ]

◆ PBLS Healthcare

$27.76

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

0/20

Pullback

12/25

Volume

11/15

Valuation

2/20

TP/AR

2/10

Options

0/10

RSI

38.6

Sup Dist

5.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

0/25

Growth

4/30

Estimates

0/20

Inst/Vol

0/15

Options

0/10

EPS Yr

EPS NY

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

1/30

Growth

0/25

Stability

5/10

LT Trend

0/5

Quality

PBLS — P/E HistoricalBiotechnology

Parabilis Medicines, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 145

Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.

PBLS

Latest News

—

Caricamento notizie per PBLS…

stock quote shares PBLS – Parabilis Medicines Inc Stock Price stock today

news today PBLS – Parabilis Medicines Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PBLS – Parabilis Medicines Inc yahoo finance google finance

stock history PBLS – Parabilis Medicines Inc invest stock market

stock prices PBLS premarket after hours

ticker PBLS fair value insiders trading

ROIV – Roivant Sciences Ltd

ROIV — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.43

Margin Of Safety %

Put/Call OI Ratio

0.41

EPS Next Q Diff

0.06

EPS Last/This Y

-1.07

EPS This/Next Y

-0.06

Price

35.07

Target Price

39.04

Analyst Recom

1.21

Performance Q

26.46

Upside

-150.0%

Beta

1.11

Ticker: ROIV

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	ROIV	28.27	0.62	1.18	43452
2026-06-03	ROIV	28.69	0.62	0.04	43413
2026-06-04	ROIV	29.51	0.62	0.07	43425
2026-06-05	ROIV	28.57	0.62	1.21	43435
2026-06-08	ROIV	28.5	0.62	0.33	43463
2026-06-09	ROIV	29.04	0.62	0.00	43474
2026-06-10	ROIV	28.41	0.62	0.03	43486
2026-06-11	ROIV	29.74	0.62	0.09	43484
2026-06-12	ROIV	30.06	0.62	0.05	43477
2026-06-15	ROIV	30.01	0.62	0.03	43460
2026-06-16	ROIV	30.41	0.62	0.13	43451
2026-06-17	ROIV	31.2	0.62	18.67	43490
2026-06-18	ROIV	31.41	0.57	0.02	42323
2026-06-22	ROIV	31.25	0.52	0.57	35747
2026-06-23	ROIV	32.21	0.52	1.74	35768
2026-06-24	ROIV	34.03	0.53	0.04	36049
2026-06-25	ROIV	34.02	0.39	4.86	45991
2026-06-26	ROIV	34.06	0.40	0.03	46534
2026-06-29	ROIV	34.74	0.40	2.26	46552
2026-06-30	ROIV	35.4	0.42	0.00	48630
2026-07-01	ROIV	35.07	0.41	1.18	48730
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-02	ROIV	28.20	-42.2	-	-1.50
2026-06-03	ROIV	28.70	-42.2	-	-1.50
2026-06-04	ROIV	29.52	-42.2	-	-1.50
2026-06-05	ROIV	28.57	-42.2	-	-1.50
2026-06-08	ROIV	28.49	-42.2	-	-1.50
2026-06-09	ROIV	29.04	-42.2	-	-1.50
2026-06-10	ROIV	28.41	-42.2	-	-1.50
2026-06-11	ROIV	29.73	-42.2	-	-1.50
2026-06-12	ROIV	30.05	-42.2	-	-1.50
2026-06-15	ROIV	30.02	-42.2	-	-1.50
2026-06-16	ROIV	30.41	-42.2	-	-1.50
2026-06-17	ROIV	31.19	-42.2	-	-1.50
2026-06-18	ROIV	31.40	-42.2	-	-1.50
2026-06-22	ROIV	31.24	-42.2	-	-1.50
2026-06-23	ROIV	32.21	-42.2	-	-1.50
2026-06-24	ROIV	34.05	-42.2	-	-1.50
2026-06-25	ROIV	34.02	-42.2	-	-1.50
2026-06-26	ROIV	34.06	-42.2	-	-1.50
2026-06-29	ROIV	34.74	-42.2	-	-1.50
2026-06-30	ROIV	35.40	-42.2	-	-1.50
2026-07-01	ROIV	35.07	-42.2	-	-1.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	ROIV	-9.21	4.47	5.30
2026-06-03	ROIV	-9.21	4.47	5.30
2026-06-04	ROIV	-9.21	4.47	5.30
2026-06-05	ROIV	-9.21	4.47	5.30
2026-06-08	ROIV	-9.21	4.51	5.30
2026-06-09	ROIV	-9.21	4.51	5.30
2026-06-10	ROIV	-9.21	4.51	7.02
2026-06-11	ROIV	-9.21	4.51	7.02
2026-06-12	ROIV	-9.17	4.51	7.01
2026-06-15	ROIV	-9.17	4.52	7.01
2026-06-16	ROIV	-7.89	4.52	7.01
2026-06-17	ROIV	-7.89	4.52	7.01
2026-06-18	ROIV	-7.15	4.52	7.01
2026-06-22	ROIV	-4.92	4.51	7.01
2026-06-23	ROIV	-4.91	4.51	7.01
2026-06-24	ROIV	-4.91	4.51	7.01
2026-06-25	ROIV	-4.91	4.51	7.01
2026-06-26	ROIV	-4.91	4.51	6.43
2026-06-29	ROIV	-5.00	4.51	6.43
2026-06-30	ROIV	-5.15	4.51	6.43
2026-07-01	ROIV	-6.54	4.51	6.43
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.46

Avg. EPS Est. Current Quarter

-0.36

Avg. EPS Est. Next Quarter

-0.4

Insider Transactions

-6.54

Institutional Transactions

4.51

Beta

1.11

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

2.3

Max Drawdown 5-Year %

Target Price

39.04

P/E

Forward P/E

PEG

P/S

3050.37

P/B

5.57

P/Free Cash Flow

EPS

-0.5

Average EPS Est. Cur. Y

-1.5

EPS Next Y. (Est.)

-1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3629.19

Relative Volume

0.74

Return on Equity vs Sector %

-34.3

Return on Equity vs Industry %

-17.3

EPS 1 7Days Diff

-0.3

EPS 1 30Days Diff

-0.34

EBIT Estimation

◆ ROIV Healthcare

$35.03

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

10/20

Pullback

8/25

Volume

9/15

Valuation

4/20

TP/AR

4/10

Options

6/10

RSI

73.3

Range 1M

89.2%

Sup Dist

0.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

10/25

Growth

12/30

Estimates

3/20

Inst/Vol

8/15

Options

6/10

EPS Yr

-132%

EPS NY

21.8%

52W%

96.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +11.4% upside

Quality

6/30

Valuation

4/30

Growth

10/25

Stability

7/10

LT Trend

4/5

Upside

+11.4%

Quality

ROIV — P/E HistoricalBiotechnology

Roivant Sciences Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 721

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

ROIV

Latest News

—

Caricamento notizie per ROIV…

stock quote shares ROIV – Roivant Sciences Ltd Stock Price stock today

news today ROIV – Roivant Sciences Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch ROIV – Roivant Sciences Ltd yahoo finance google finance

stock history ROIV – Roivant Sciences Ltd invest stock market

stock prices ROIV premarket after hours

ticker ROIV fair value insiders trading

RNAM – Avidity Biosciences Inc

RNAM — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

6.18

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

72.82

Target Price

Analyst Recom

Performance Q

2.13

Upside

N/A

Beta

0.98

Ticker: RNAM

9 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	RNAM	72.82	N/A	N/A	0
2026-06-03	RNAM	72.82	N/A	N/A	0
2026-06-04	RNAM	72.82	N/A	N/A	0
2026-06-05	RNAM	72.82	N/A	N/A	0
2026-06-08	RNAM	72.82	N/A	N/A	0
2026-06-09	RNAM	72.82	N/A	N/A	0
2026-06-10	RNAM	72.82	N/A	N/A	0
2026-06-11	RNAM	72.82	N/A	N/A	0
2026-06-12	RNAM	72.82	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

9 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

0.98

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

602.56

P/B

6.52

P/Free Cash Flow

EPS

-4.96

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-3650.39

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

No data found for RNAM

RNAM — P/E HistoricalBiotechnology

RNAM

Latest News

—

Caricamento notizie per RNAM…

stock quote shares RNAM – Avidity Biosciences Inc Stock Price stock today

news today RNAM – Avidity Biosciences Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch RNAM – Avidity Biosciences Inc yahoo finance google finance

stock history RNAM – Avidity Biosciences Inc invest stock market

stock prices RNAM premarket after hours

ticker RNAM fair value insiders trading

RGC – Regencell Bioscience Holdings Ltd

RGC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

1.34

Margin Of Safety %

Put/Call OI Ratio

1.51

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

7.96

Target Price

Analyst Recom

Performance Q

-68.42

Upside

-101.6%

Beta

1.83

Ticker: RGC

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	RGC	23.3	1.16	0.33	5465
2026-06-03	RGC	23.75	1.13	0.03	5609
2026-06-04	RGC	22.2	1.12	1.13	5656
2026-06-05	RGC	20.07	1.11	0.81	5680
2026-06-08	RGC	21.67	1.08	0.11	5901
2026-06-09	RGC	20.19	1.00	0.11	6214
2026-06-10	RGC	20.6	0.99	7.39	6311
2026-06-11	RGC	19.62	1.00	2.87	6343
2026-06-12	RGC	19.19	1.05	2.09	6489
2026-06-15	RGC	17.35	1.06	3.39	6636
2026-06-16	RGC	17.2	1.07	1.62	6828
2026-06-17	RGC	14.77	1.06	1.24	6925
2026-06-18	RGC	11.87	1.03	4.74	6953
2026-06-22	RGC	10.35	1.15	3.82	2725
2026-06-23	RGC	11.1	2.05	0.48	5892
2026-06-24	RGC	8.57	1.62	0.74	6570
2026-06-25	RGC	7.47	1.46	1.55	7192
2026-06-26	RGC	6.35	1.38	2.99	7222
2026-06-29	RGC	6.27	1.63	0.37	8167
2026-06-30	RGC	6.17	1.55	0.92	8505
2026-07-01	RGC	8.13	1.51	0.26	8586
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-02	RGC	23.33	-	-	-
2026-06-03	RGC	23.75	-	-	-
2026-06-04	RGC	22.20	-	-	-
2026-06-05	RGC	20.13	-	-	-
2026-06-08	RGC	21.58	-	-	-
2026-06-09	RGC	20.19	-	-	-
2026-06-10	RGC	20.47	-	-	-
2026-06-11	RGC	19.68	-	-	-
2026-06-12	RGC	19.00	-	-	-
2026-06-15	RGC	17.09	-	-	-
2026-06-16	RGC	17.00	-	-	-
2026-06-17	RGC	14.71	-	-	-
2026-06-18	RGC	12.25	-	-	-
2026-06-22	RGC	10.35	-	-	-
2026-06-23	RGC	10.87	-	-	-
2026-06-24	RGC	8.72	-	-	-
2026-06-25	RGC	7.52	-	-	-
2026-06-26	RGC	6.38	-	-	-
2026-06-29	RGC	6.26	-	-	-
2026-06-30	RGC	6.13	-	-	-
2026-07-01	RGC	7.96	-	-	-
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	RGC	0.00	10.68	1.42
2026-06-03	RGC	0.00	10.68	1.42
2026-06-04	RGC	0.00	10.68	1.42
2026-06-05	RGC	0.00	10.68	1.42
2026-06-08	RGC	0.00	10.68	1.42
2026-06-09	RGC	0.00	10.68	1.42
2026-06-10	RGC	0.00	10.68	1.39
2026-06-11	RGC	0.00	10.68	1.39
2026-06-12	RGC	0.00	10.68	1.39
2026-06-15	RGC	0.00	11.24	1.39
2026-06-16	RGC	0.00	11.24	1.39
2026-06-17	RGC	0.00	11.24	1.39
2026-06-18	RGC	0.00	11.24	1.39
2026-06-22	RGC	0.00	11.73	1.39
2026-06-23	RGC	0.00	11.73	1.39
2026-06-24	RGC	0.00	11.73	1.39
2026-06-25	RGC	0.00	11.73	1.39
2026-06-26	RGC	0.00	11.73	1.34
2026-06-29	RGC	0.00	11.73	1.34
2026-06-30	RGC	0.00	11.73	1.34
2026-07-01	RGC	0.00	11.73	1.34
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

11.73

Beta

1.83

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

90.5

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

3251.01

P/Free Cash Flow

EPS

-0.01

Average EPS Est. Cur. Y

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

15.14

Return on Equity vs Sector %

-100

Return on Equity vs Industry %

-100

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ RGC Healthcare

$8.03

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

2/20

Pullback

5/25

Volume

3/15

Valuation

6/20

TP/AR

2/10

Options

1/10

RSI

25.1

Range 1M

11.9%

Sup Dist

29.9%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

6/25

Growth

7/30

Estimates

0/20

Inst/Vol

8/15

Options

5/10

EPS Yr

EPS NY

52W%

3.6%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

Quality

2/30

Valuation

2/30

Growth

3/25

Stability

5/10

LT Trend

1/5

Quality

RGC — P/E HistoricalDrug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings L

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 10

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

RGC

Latest News

—

Caricamento notizie per RGC…

stock quote shares RGC – Regencell Bioscience Holdings Ltd Stock Price stock today

news today RGC – Regencell Bioscience Holdings Ltd stock forecast ,stock prediction 2023 2024 2025

marketwatch RGC – Regencell Bioscience Holdings Ltd yahoo finance google finance

stock history RGC – Regencell Bioscience Holdings Ltd invest stock market

stock prices RGC premarket after hours

ticker RGC fair value insiders trading

ONC – BeOne Medicines Ltd ADR

ONC — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.89

Margin Of Safety %

-4

Put/Call OI Ratio

0.8

EPS Next Q Diff

-0.23

EPS Last/This Y

-1.47

EPS This/Next Y

3.12

Price

290.82

Target Price

414.19

Analyst Recom

1.25

Performance Q

-2.1

Upside

-46.1%

Beta

0.49

Ticker: ONC

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	ONC	274.5	1.16	3.26	1671
2026-06-03	ONC	279.26	1.17	7.00	1687
2026-06-04	ONC	279.86	1.19	1.67	1703
2026-06-05	ONC	270.08	1.19	0.30	1716
2026-06-08	ONC	270.66	1.16	0.23	1769
2026-06-09	ONC	268.06	1.18	0.04	1761
2026-06-10	ONC	263.38	1.04	0.03	1677
2026-06-11	ONC	260.33	0.76	4.91	1977
2026-06-12	ONC	264.48	0.76	0.58	1976
2026-06-15	ONC	268.47	0.76	0.00	1970
2026-06-16	ONC	264.21	0.75	0.39	1979
2026-06-17	ONC	262.68	0.71	1.67	1936
2026-06-18	ONC	270.61	0.70	0.19	1932
2026-06-22	ONC	272.14	0.74	0.78	1821
2026-06-23	ONC	276.08	0.75	6.89	1821
2026-06-24	ONC	277.39	0.79	0.19	1877
2026-06-25	ONC	275.31	0.78	0.29	1896
2026-06-26	ONC	279.99	0.78	0.25	1904
2026-06-29	ONC	290.11	0.77	0.92	1910
2026-06-30	ONC	284.98	0.79	5.00	2219
2026-07-01	ONC	290.79	0.80	0.25	2243
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-02	ONC	275.05	89.6	54.0	6.69
2026-06-03	ONC	278.60	89.6	86.7	6.69
2026-06-04	ONC	280.66	89.6	80.4	6.69
2026-06-05	ONC	270.00	89.6	60.3	6.69
2026-06-08	ONC	270.10	89.6	82.9	6.62
2026-06-09	ONC	268.53	89.6	83.2	6.62
2026-06-10	ONC	263.74	89.6	83.9	6.62
2026-06-11	ONC	260.80	89.6	57.2	6.62
2026-06-12	ONC	264.94	89.6	115.1	6.62
2026-06-15	ONC	264.48	89.6	98.2	6.59
2026-06-16	ONC	264.75	89.6	86.9	6.59
2026-06-17	ONC	261.52	89.6	79.0	6.59
2026-06-18	ONC	270.51	89.6	137.9	6.59
2026-06-22	ONC	270.92	89.6	96.6	6.59
2026-06-23	ONC	275.04	89.6	118.6	6.59
2026-06-24	ONC	276.92	89.6	127.7	6.59
2026-06-25	ONC	276.44	89.6	123.0	6.59
2026-06-26	ONC	280.60	89.6	80.3	6.59
2026-06-29	ONC	290.18	89.6	123.7	6.59
2026-06-30	ONC	285.10	89.6	67.6	6.59
2026-07-01	ONC	290.82	89.6	106.0	6.59
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	ONC	-17.86	-1.64	1.03
2026-06-03	ONC	-17.86	-1.64	1.03
2026-06-04	ONC	-17.88	-1.64	1.03
2026-06-05	ONC	-17.88	-1.64	1.03
2026-06-08	ONC	-17.88	-1.54	1.03
2026-06-09	ONC	-17.88	-1.54	1.03
2026-06-10	ONC	-17.88	-1.54	1.07
2026-06-11	ONC	-18.99	-1.54	1.07
2026-06-12	ONC	-18.99	-1.54	1.07
2026-06-15	ONC	-18.90	-1.67	1.07
2026-06-16	ONC	-19.46	-1.67	1.07
2026-06-17	ONC	-19.46	-1.67	1.07
2026-06-18	ONC	-5.09	-1.67	1.07
2026-06-22	ONC	-6.23	-1.65	1.07
2026-06-23	ONC	-6.23	-1.65	1.07
2026-06-24	ONC	-6.23	-1.65	1.07
2026-06-25	ONC	-6.23	-1.65	1.07
2026-06-26	ONC	-7.18	-1.65	0.89
2026-06-29	ONC	-7.18	-1.68	0.89
2026-06-30	ONC	-7.18	-1.68	0.89
2026-07-01	ONC	-7.18	-1.68	0.89
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

1.96

Avg. EPS Est. Current Quarter

1.59

Avg. EPS Est. Next Quarter

1.73

Insider Transactions

-7.18

Institutional Transactions

-1.68

Beta

0.49

Average Sales Estimate Current Quarter

1594

Average Sales Estimate Next Quarter

1667

Fair Value

280.25

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

31.8

Max Drawdown 5-Year %

-70

Target Price

414.19

P/E

64.88

Forward P/E

30.22

PEG

0.43

P/S

5.17

P/B

6.79

P/Free Cash Flow

26.61

EPS

4.48

Average EPS Est. Cur. Y

6.59

EPS Next Y. (Est.)

9.72

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

8.94

Relative Volume

1.35

Return on Equity vs Sector %

-16.9

Return on Equity vs Industry %

0.1

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

106

◆ ONC Healthcare

$290.74

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

8/25

Volume

3/15

Valuation

15/20

TP/AR

2/10

Options

4/10

RSI

58.2

Range 1M

92%

Sup Dist

2.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

3/25

Growth

28/30

Estimates

5/20

Inst/Vol

3/15

Options

7/10

EPS Yr

154.4%

EPS NY

43.8%

52W%

35%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +15.9% upside

Quality

14/30

Valuation

7/30

Growth

21/25

Stability

5/10

LT Trend

0/5

Upside

+15.9%

Quality

MoS

-4%

ONC — P/E HistoricalBiotechnology

BeOne Medicines Ltd.

Sector: Healthcare

Industry: Biotechnology

Employees: 12000

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

ONC

Latest News

—

Caricamento notizie per ONC…

stock quote shares ONC – BeOne Medicines Ltd ADR Stock Price stock today

news today ONC – BeOne Medicines Ltd ADR stock forecast ,stock prediction 2023 2024 2025

marketwatch ONC – BeOne Medicines Ltd ADR yahoo finance google finance

stock history ONC – BeOne Medicines Ltd ADR invest stock market

stock prices ONC premarket after hours

ticker ONC fair value insiders trading

MDLN – Medline Inc

MDLN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

5.12

Margin Of Safety %

Put/Call OI Ratio

2.09

EPS Next Q Diff

0.06

EPS Last/This Y

0.09

EPS This/Next Y

0.15

Price

41.76

Target Price

50.93

Analyst Recom

1.57

Performance Q

-6.22

Upside

-36.7%

Beta

Ticker: MDLN

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-06-02	MDLN	33.18	0.46	2.58	18694
2026-06-03	MDLN	34.47	0.47	0.13	19347
2026-06-04	MDLN	34.46	0.47	0.28	19590
2026-06-05	MDLN	33.59	0.47	0.63	19827
2026-06-08	MDLN	33.81	0.47	0.65	19892
2026-06-09	MDLN	36.02	0.47	0.12	20323
2026-06-10	MDLN	36.54	0.46	1.12	20525
2026-06-11	MDLN	37.12	0.46	0.81	20564
2026-06-12	MDLN	36.62	0.46	17.61	20569
2026-06-15	MDLN	37.34	0.56	7.22	22050
2026-06-16	MDLN	37.1	0.68	0.75	23914
2026-06-17	MDLN	36.42	0.69	6.68	23890
2026-06-18	MDLN	35.88	0.64	0.44	23257
2026-06-22	MDLN	34.7	0.62	0.98	20097
2026-06-23	MDLN	35.28	0.62	1.88	20159
2026-06-24	MDLN	36.05	0.63	3.71	20716
2026-06-25	MDLN	37.81	0.63	0.36	21304
2026-06-26	MDLN	38.84	0.63	0.63	21429
2026-06-29	MDLN	39.63	0.62	40.86	21437
2026-06-30	MDLN	39.41	2.10	2.90	41234
2026-07-01	MDLN	41.77	2.09	1.27	41386
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-06-02	MDLN	33.19	-	500.1	1.51
2026-06-03	MDLN	34.43	-	709.1	1.51
2026-06-04	MDLN	34.45	-	640.0	1.51
2026-06-05	MDLN	33.60	-	592.2	1.51
2026-06-08	MDLN	33.79	-	649.6	1.51
2026-06-09	MDLN	36.01	-	762.6	1.51
2026-06-10	MDLN	36.54	-	667.2	1.51
2026-06-11	MDLN	37.13	-	670.6	1.51
2026-06-12	MDLN	36.62	-	612.2	1.51
2026-06-15	MDLN	37.35	-	677.6	1.51
2026-06-16	MDLN	37.09	-	625.5	1.51
2026-06-17	MDLN	36.42	-	604.3	1.51
2026-06-18	MDLN	35.89	-	610.9	1.51
2026-06-22	MDLN	34.71	-	573.4	1.51
2026-06-23	MDLN	35.33	-	672.9	1.51
2026-06-24	MDLN	36.05	-	679.5	1.51
2026-06-25	MDLN	37.80	-	731.6	1.51
2026-06-26	MDLN	38.83	-	691.1	1.51
2026-06-29	MDLN	39.64	-	680.2	1.51
2026-06-30	MDLN	39.42	-	629.0	1.51
2026-07-01	MDLN	41.76	-	755.7	1.51
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-06-02	MDLN	-36.98	9.18	4.87
2026-06-03	MDLN	-36.98	9.18	4.87
2026-06-04	MDLN	-36.98	9.18	4.87
2026-06-05	MDLN	-36.98	9.18	4.24
2026-06-08	MDLN	-41.58	9.20	4.24
2026-06-09	MDLN	-41.58	9.20	4.24
2026-06-10	MDLN	-41.58	9.20	4.33
2026-06-11	MDLN	-41.58	9.20	4.33
2026-06-12	MDLN	-41.58	9.20	4.33
2026-06-15	MDLN	-42.58	9.22	4.23
2026-06-16	MDLN	-42.58	9.22	4.23
2026-06-17	MDLN	-42.58	9.22	4.23
2026-06-18	MDLN	-42.58	9.22	4.23
2026-06-22	MDLN	-53.54	9.22	4.23
2026-06-23	MDLN	-48.10	9.22	4.23
2026-06-24	MDLN	-37.36	9.22	4.23
2026-06-25	MDLN	-37.36	9.22	4.27
2026-06-26	MDLN	-36.99	9.22	5.12
2026-06-29	MDLN	-37.49	9.22	5.12
2026-06-30	MDLN	-37.49	9.22	5.12
2026-07-01	MDLN	-37.49	9.22	5.12
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

0.33

Avg. EPS Est. Current Quarter

0.32

Avg. EPS Est. Next Quarter

0.39

Insider Transactions

-37.49

Institutional Transactions

9.22

Beta

Average Sales Estimate Current Quarter

7518

Average Sales Estimate Next Quarter

7723

Fair Value

49.7

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

17.9

Max Drawdown 5-Year %

Target Price

50.93

P/E

34.9

Forward P/E

25.18

PEG

2.68

P/S

1.88

P/B

3.13

P/Free Cash Flow

52.46

EPS

1.2

Average EPS Est. Cur. Y

1.51

EPS Next Y. (Est.)

1.67

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.32

Relative Volume

1.23

Return on Equity vs Sector %

-19.1

Return on Equity vs Industry %

-0.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

755.7

◆ MDLN Healthcare

$41.73

📉

Swing / Pullback

Buy the dip on strong trends

WEAK

Trend

16/20

Pullback

4/25

Volume

4/15

Valuation

16/20

TP/AR

1/10

Options

2/10

RSI

66.8

Range 1M

95.7%

Sup Dist

7.2%

🚀

Momentum Growth

Ride accelerating trends

WEAK

Momentum

14/25

Growth

11/30

Estimates

2/20

Inst/Vol

7/15

Options

3/10

EPS Yr

5.8%

EPS NY

9.5%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟡 HOLD +4.1% upside

Quality

3/30

Valuation

7/30

Growth

7/25

Stability

5/10

LT Trend

1/5

Upside

+4.1%

Quality

MoS

19%

MDLN — P/E HistoricalMedical Instruments & Supplies

Medline Inc.

Sector: Healthcare

Industry: Medical Instruments & Supplies

Employees: 45000

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front line care, and laboratory and diagnostics. Its front line care offers med-surg products for patient-facing needs, including wound care products, exam gloves, skin care and incontinence products, environment cleaning supplies, textiles, hand sanitizer, durable medical equipment, patient plastics, and decolonization and infection control products. Its surgical solutions provide operating room and perioperative environment product solutions, including surgical procedure trays, drapes and gowns, personal protective equipment, sterile wraps, surgical instruments, surgeon's gloves, procedure kits, and orthopedic implants. Its laboratory and diagnostics offer laboratory and diagnostic product solutions, including point of care testing, analyzers and instrumentation, lab and diagnostic consumables, diagnostic instruments, vital signs monitors, and anatomic pathology and phlebotomy products. It provides its products to domestic and international consumers. The Supply Chain Solutions segment procures and distributes a variety of third-party products from national brands. It provides logistics and supply chain optimization services to domestic and international consumers. It also provides supply chain optimization services, such as consulting engagements, outsourced warehouse and technology management, put-away-ready packaging, third-party logistics, inventory rationalization, and route planning. The company was founded in 1966 and is based in Northfield, Illinois.

MDLN

Latest News

—

Caricamento notizie per MDLN…

stock quote shares MDLN – Medline Inc Stock Price stock today

news today MDLN – Medline Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MDLN – Medline Inc yahoo finance google finance

stock history MDLN – Medline Inc invest stock market

stock prices MDLN premarket after hours

ticker MDLN fair value insiders trading

No more stocks to show

PBLS – Parabilis Medicines Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PBLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

ROIV – Roivant Sciences Ltd

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ROIV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y

Last Quarter Act. EPS

Average EPS Est. Cur. Y